InventisBio Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Shanghai China (2013)

Organization Overview

First Clinical Trial
2017
NCT03291782
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

InventisBio Co., Ltd | InventisBio Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

d-0120 (3 trials)

d-0316 (2 trials)

d-1553 (1 trial)

Drugs in Phase 1 Trials (2)

d-0502 (2 trials)

palbociclib (ibrance) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Hyperuricemia (Phase 2)

Lung Neoplasms (Phase 1)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 5